Stockwinners Market Radar for December 22, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:31 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Walmart (WMT) plans to place its giant brick-and-mortar stores at the center of its strategy to take on its web-based retail rival Amazon (AMZN), The Wall Street Journal's Sarah Nassauer reported. Walmart, boss Doug McMillon told executives at a meeting, wasn't going to win by building an unprofitable e-commerce operation or other stand-alone ventures. Instead, its supercenters could be the heart of a web of businesses all working together to attract shoppers and drive profits, the report added. 2. Johnson & Johnson (JNJ) is not responsible for a Missouri woman's cancer that she blamed on asbestos-tainted talc, a jury decided in the company's latest win in the nationwide litigation over its iconic baby powder, Bloomberg's Jef Feeley reported. Jurors in state court in St. Louis concluded Friday J&J's talc-based product did not contribute to the development of Vickie Forrest's ovarian cancer and didn't fail to properly warn her about its health risks, the report added. 3. Becton Dickinson (BDX) stock is up nearly 20% this year, but still trails S&P 500 index by almost 10 percentage points and many of its peers this year, in part due to heightened regulatory scrutiny of a product, Lawrence Strauss wrote in this week's edition of Barron's. However, hurdles may be causing some investors to overlook a solid company, he added. 4. Disney's (DIS) "Star Wars: The Rise of Skywalker" won this weekend's North American box office with $175.5M, earning $373.5M globally. The movie is, however, the first "Star Wars" pic made by Lucasfilm and Disney not to earn an A or A- from audiences. "The Rise of Skywalker" sports a B+ CinemaScore and a 57% Rotten Tomatoes rating. 5. China Mobile (CHL) saw a positive mention in this week's edition of Barron's.

18:08 EST BeiGene announces acceptance of supplemental NDA in China for REVLIMID - BeiGene (BGNE) announced that the China National Medical Products Administration has accepted a supplemental new drug application for REVLIMID, in combination with rituximab, for the treatment of patients with relapsed or refractory indolent lymphoma. REVLIMID was first approved in China in 2013 for the treatment of multiple myeloma in combination with dexamethasone, in adult patients who have received at least one prior therapy, and the label for the combination was expanded in 2018 to include adult patients with newly-diagnosed multiple myeloma who are not eligible for transplant. It is currently marketed in China by BeiGene under an exclusive license from Celgene Logistics Sarl, a Bristol-Myers Squibb (BMY) company. The sNDA is supported by a clinical, non-clinical, and chemistry, manufacturing and control data package, including the results from the pivotal Phase 3 AUGMENT study sponsored and conducted by Bristol-Myers Squibb. AUGMENT is a randomized, double-blind, multicenter trial in which a total of 358 patients with relapsed or refractory follicular or marginal zone lymphoma were randomized 1:1 to receive REVLIMID and rituximab or rituximab and placebo. With a median follow-up of 28.3 months, R2 demonstrated clinically meaningful and statistically significant improvement in progression-free survival, evaluated by an independent review committee, relative to the control arm with a 54% reduction in the risk of progression or death. The median PFS was 39.4 months for the R2 arm and 14.1 months for the control arm with an improvement by more than 2 years. Overall response rate, a secondary endpoint, was 78% in the R2 arm vs. 53% in the control arm, as assessed by the IRC. Duration of response was significantly improved for R2 vs. control with median DoR of 37 vs. 22 months, respectively. The most frequent adverse event in the R2 arm was neutropenia, vs. 22% in the control arm. Additional commonly observed AEs in more than 20% of patients included diarrhea, constipation, cough, and fatigue. Adverse events that were reported at a higher rate in the R2 arm were neutropenia, constipation, leukopenia, anemia, thrombocytopenia and tumor flare.

15:53 EST Station Casinos team members reject Culinary Workers Union Local 226 - With over 84% turnout, Station Casinos Team Members at Red Rock Casino, Resort and Spa have decisively rejected the Culinary Workers Union Local 226. The election was held over the course of several days by secret ballot and supervised by the National Labor Relations Board. Station Casinos Team Members by a wide margin of 9%, 54% over 45%, have rejected unionization. Red Rock Casino, Resort and Spa Vice President and General Manager Scott Nelson said, "Our great Team Members have spoken, and we thank them for their support. We believe there is no better place to work in Las Vegas and these election results validate that belief."

15:34 EST ExpressJet Airlines, TWU reach tentative agreement covering dispatchers - ExpressJet Airlines, a United Express carrier, announced today that it has reached a tentative agreement with the Transport Workers Union covering the carrier's Dispatchers. "This new agreement recognizes the valuable operational role our Dispatchers play in ensuring ExpressJet's future growth as a trusted United Express Partner," said Larry Snyder, Managing Director of the Operations Support Center. Representatives from TWU and ExpressJet negotiated a four-year agreement that raises wages and acknowledges the continued contributions of ExpressJet's Flight Dispatchers who work in the carrier's Operation Support Center in Atlanta, GA.

14:42 EST Hess announces first production from Liza Field, Offshore Guyana - Hess (HES) announced startup of production from the Liza Field offshore Guyana, less than five years after the first discovery of hydrocarbons and well ahead of the industry average for deepwater developments. Production from the first phase of the Liza Field, located in the Stabroek Block, is expected to reach full capacity of 120,000 gross barrels of oil per day in the coming months, with the first cargo set to be sold within several weeks. The Liza Phase 1 development project utilizes the Liza Destiny floating, production, storage and offloading vessel moored approximately 120 miles offshore Guyana, with four undersea drill centers supporting 17 wells. A second FPSO, Liza Unity, with a capacity of up to 220,000 gross barrels of oil per day is under construction to support the Liza Phase 2 development, and front-end engineering design is underway for a potential third FPSO, the Prosperity, to develop the Payara field upon government and regulatory approvals. The Stabroek Block is 6.6M acres. Current gross discovered recoverable resources are estimated to be more than 6B barrels of oil equivalent. At least five FPSOs are expected to be producing more than 750,000 gross barrels of oil per day from the Stabroek Block by 2025. Exxon Mobil (XOM) affiliate Esso Exploration and Production Guyana Limited is operator and holds 45% interest in the Stabroek Block. Hess Guyana Exploration holds 30% interest and CNOOC Petroleum Guyana Limited, a wholly-owned subsidiary of CNOOC Limited, holds 25% interest.

14:05 EST Boeing Starliner completes first orbital flight test - The Boeing CST-100 Starliner's first mission ended "historically when it became the first American orbital space capsule to land on American soil rather than in an ocean," the company said. The spacecraft's crew module landed at the U.S. Army's White Sands Missile Range at 5:48 a.m. Mountain time, after spending just over two days on orbit and checking off a number of flight test objectives. The last time a spacecraft landed at the White Sands Space Harbor runway was in 1982, when Space Shuttle Columbia touched down, ending its STS-3 mission. Shortly after its December 20 launch and separation from its booster rocket, Starliner experienced a mission timing anomaly that made it use too much fuel to reach the intended destination of the International Space Station. Flight controllers were able to address the issue and put Starliner into a lower, stable orbit. The vehicle demonstrated key systems and capabilities before being signaled to return to Earth. Although this Starliner carried no people, it did have a passenger. An anthropometric test device, named "Rosie," was in the commander's seat for the entire mission. She was outfitted with about a dozen sensors that collected data to help prove Starliner is safe for future human crews. Next, this crew module will be returned to Florida for data retrieval, analysis and refurbishment for future missions. It is the vehicle chosen to fly NASA astronauts Sunita "Suni" Williams and Josh Cassada, along with two international partner astronauts, on the first operational mission. In parallel, Boeing's Starliner team is finalizing the vehicle that will fly Boeing astronaut Chris Ferguson and NASA astronauts Mike Fincke and Nicole Mann on the Crewed Flight Test.